nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—CYP3A4—bone cancer	0.506	1	CbGaD
Mefloquine—BCHE—Cisplatin—bone cancer	0.0798	0.54	CbGbCtD
Mefloquine—ABCB1—Cisplatin—bone cancer	0.0203	0.137	CbGbCtD
Mefloquine—HBA1—forelimb—bone cancer	0.0158	0.133	CbGeAlD
Mefloquine—HBA2—leg—bone cancer	0.0147	0.123	CbGeAlD
Mefloquine—HBA2—forelimb—bone cancer	0.0145	0.122	CbGeAlD
Mefloquine—HBA1—hindlimb—bone cancer	0.0143	0.12	CbGeAlD
Mefloquine—ABCB1—Doxorubicin—bone cancer	0.0136	0.0919	CbGbCtD
Mefloquine—ABCB1—Methotrexate—bone cancer	0.0132	0.089	CbGbCtD
Mefloquine—HBA2—hindlimb—bone cancer	0.0131	0.11	CbGeAlD
Mefloquine—CYP2D6—Doxorubicin—bone cancer	0.0128	0.0866	CbGbCtD
Mefloquine—HBA1—appendage—bone cancer	0.0122	0.103	CbGeAlD
Mefloquine—HBA2—appendage—bone cancer	0.0112	0.0945	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—bone cancer	0.00814	0.0551	CbGbCtD
Mefloquine—HBA1—connective tissue—bone cancer	0.00349	0.0294	CbGeAlD
Mefloquine—HBA2—connective tissue—bone cancer	0.0032	0.027	CbGeAlD
Mefloquine—HBA1—bone marrow—bone cancer	0.00232	0.0196	CbGeAlD
Mefloquine—HBA1—spinal cord—bone cancer	0.00231	0.0195	CbGeAlD
Mefloquine—HBA2—bone marrow—bone cancer	0.00213	0.018	CbGeAlD
Mefloquine—HBA2—spinal cord—bone cancer	0.00212	0.0179	CbGeAlD
Mefloquine—ADORA2A—spinal cord—bone cancer	0.00111	0.00931	CbGeAlD
Mefloquine—CYP19A1—Metapathway biotransformation—CYP4V2—bone cancer	0.00108	0.013	CbGpPWpGaD
Mefloquine—ADORA1—tendon—bone cancer	0.00099	0.00834	CbGeAlD
Mefloquine—ACHE—tendon—bone cancer	0.000984	0.00828	CbGeAlD
Mefloquine—CYP19A1—connective tissue—bone cancer	0.000977	0.00822	CbGeAlD
Mefloquine—ADORA1—spinal cord—bone cancer	0.000955	0.00804	CbGeAlD
Mefloquine—ACHE—spinal cord—bone cancer	0.000949	0.00799	CbGeAlD
Mefloquine—HBA2—Metabolism—NDUFA12—bone cancer	0.000925	0.0111	CbGpPWpGaD
Mefloquine—HBA1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000885	0.0107	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—TNFRSF11A—bone cancer	0.000846	0.0102	CbGpPWpGaD
Mefloquine—ADORA2A—GPCRs, Other—GRM1—bone cancer	0.000838	0.0101	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—NT5C3A—bone cancer	0.000766	0.00923	CbGpPWpGaD
Mefloquine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00073	0.00879	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—NDUFA12—bone cancer	0.000701	0.00844	CbGpPWpGaD
Mefloquine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000687	0.00827	CbGpPWpGaD
Mefloquine—HBA1—Folate Metabolism—TP53—bone cancer	0.000663	0.00799	CbGpPWpGaD
Mefloquine—ABCB1—Drug Induction of Bile Acid Pathway—CYP3A4—bone cancer	0.000651	0.00784	CbGpPWpGaD
Mefloquine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000644	0.00776	CbGpPWpGaD
Mefloquine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00064	0.00771	CbGpPWpGaD
Mefloquine—CYP19A1—Tryptophan metabolism—CYP3A4—bone cancer	0.00062	0.00747	CbGpPWpGaD
Mefloquine—ADORA2A—GPCRs, Other—SMO—bone cancer	0.00059	0.00711	CbGpPWpGaD
Mefloquine—ADORA1—G alpha (i) signalling events—GRM4—bone cancer	0.000586	0.00706	CbGpPWpGaD
Mefloquine—ADORA1—G alpha (i) signalling events—RGS1—bone cancer	0.000586	0.00706	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—NT5C3A—bone cancer	0.000581	0.00699	CbGpPWpGaD
Mefloquine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000539	0.00649	CbGpPWpGaD
Mefloquine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000518	0.00624	CbGpPWpGaD
Mefloquine—CYP19A1—Ovarian Infertility Genes—CDK4—bone cancer	0.000514	0.00619	CbGpPWpGaD
Mefloquine—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000501	0.00604	CbGpPWpGaD
Mefloquine—CYP19A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000495	0.00596	CbGpPWpGaD
Mefloquine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000481	0.00579	CbGpPWpGaD
Mefloquine—BCHE—bone marrow—bone cancer	0.000468	0.00394	CbGeAlD
Mefloquine—BCHE—spinal cord—bone cancer	0.000466	0.00393	CbGeAlD
Mefloquine—CYP19A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000406	0.00489	CbGpPWpGaD
Mefloquine—Leukopenia—Cisplatin—bone cancer	0.000401	0.00277	CcSEcCtD
Mefloquine—Dermatitis bullous—Epirubicin—bone cancer	0.0004	0.00276	CcSEcCtD
Mefloquine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000394	0.00475	CbGpPWpGaD
Mefloquine—Hepatic failure—Doxorubicin—bone cancer	0.000393	0.00272	CcSEcCtD
Mefloquine—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000393	0.00473	CbGpPWpGaD
Mefloquine—Irritability—Methotrexate—bone cancer	0.00039	0.00269	CcSEcCtD
Mefloquine—Convulsion—Cisplatin—bone cancer	0.000388	0.00268	CcSEcCtD
Mefloquine—Mood swings—Methotrexate—bone cancer	0.000387	0.00267	CcSEcCtD
Mefloquine—Ataxia—Methotrexate—bone cancer	0.000384	0.00265	CcSEcCtD
Mefloquine—Myalgia—Cisplatin—bone cancer	0.000381	0.00263	CcSEcCtD
Mefloquine—Anxiety—Cisplatin—bone cancer	0.00038	0.00262	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000379	0.00262	CcSEcCtD
Mefloquine—Discomfort—Cisplatin—bone cancer	0.000377	0.0026	CcSEcCtD
Mefloquine—Affect lability—Epirubicin—bone cancer	0.000376	0.0026	CcSEcCtD
Mefloquine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000374	0.00451	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—GNA11—bone cancer	0.000371	0.00447	CbGpPWpGaD
Mefloquine—Dermatitis bullous—Doxorubicin—bone cancer	0.00037	0.00255	CcSEcCtD
Mefloquine—ADORA1—Circadian rythm related genes—EZH2—bone cancer	0.000369	0.00445	CbGpPWpGaD
Mefloquine—Oedema—Cisplatin—bone cancer	0.000366	0.00252	CcSEcCtD
Mefloquine—Anaphylactic shock—Cisplatin—bone cancer	0.000366	0.00252	CcSEcCtD
Mefloquine—ACHE—ATF-2 transcription factor network—PLAU—bone cancer	0.000363	0.00437	CbGpPWpGaD
Mefloquine—Mood swings—Epirubicin—bone cancer	0.000362	0.0025	CcSEcCtD
Mefloquine—Ataxia—Epirubicin—bone cancer	0.000359	0.00248	CcSEcCtD
Mefloquine—Nervous system disorder—Cisplatin—bone cancer	0.000359	0.00248	CcSEcCtD
Mefloquine—Thrombocytopenia—Cisplatin—bone cancer	0.000358	0.00247	CcSEcCtD
Mefloquine—Tachycardia—Cisplatin—bone cancer	0.000357	0.00246	CcSEcCtD
Mefloquine—Skin disorder—Cisplatin—bone cancer	0.000355	0.00245	CcSEcCtD
Mefloquine—ADORA1—GPCR ligand binding—GRM4—bone cancer	0.000355	0.00427	CbGpPWpGaD
Mefloquine—Hyperhidrosis—Cisplatin—bone cancer	0.000354	0.00244	CcSEcCtD
Mefloquine—Affect lability—Doxorubicin—bone cancer	0.000348	0.0024	CcSEcCtD
Mefloquine—ACHE—ATF-2 transcription factor network—CDK4—bone cancer	0.000343	0.00413	CbGpPWpGaD
Mefloquine—Hypotension—Cisplatin—bone cancer	0.000342	0.00236	CcSEcCtD
Mefloquine—Muscular weakness—Epirubicin—bone cancer	0.000337	0.00233	CcSEcCtD
Mefloquine—HBA2—Metabolism—ENO2—bone cancer	0.000336	0.00404	CbGpPWpGaD
Mefloquine—Mood swings—Doxorubicin—bone cancer	0.000335	0.00231	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000333	0.0023	CcSEcCtD
Mefloquine—Ataxia—Doxorubicin—bone cancer	0.000332	0.0023	CcSEcCtD
Mefloquine—Paraesthesia—Cisplatin—bone cancer	0.000328	0.00227	CcSEcCtD
Mefloquine—Dyspnoea—Cisplatin—bone cancer	0.000326	0.00225	CcSEcCtD
Mefloquine—Decreased appetite—Cisplatin—bone cancer	0.000318	0.00219	CcSEcCtD
Mefloquine—Pneumonia—Methotrexate—bone cancer	0.000316	0.00219	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Cisplatin—bone cancer	0.000316	0.00218	CcSEcCtD
Mefloquine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000314	0.00378	CbGpPWpGaD
Mefloquine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000312	0.00215	CcSEcCtD
Mefloquine—Muscular weakness—Doxorubicin—bone cancer	0.000312	0.00215	CcSEcCtD
Mefloquine—HBA2—Metabolism—DHFR—bone cancer	0.000311	0.00375	CbGpPWpGaD
Mefloquine—Renal failure—Methotrexate—bone cancer	0.000309	0.00214	CcSEcCtD
Mefloquine—ADORA1—GPCR ligand binding—GRM1—bone cancer	0.000308	0.0037	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000306	0.00369	CbGpPWpGaD
Mefloquine—Sweating—Methotrexate—bone cancer	0.000302	0.00208	CcSEcCtD
Mefloquine—Feeling abnormal—Cisplatin—bone cancer	0.000301	0.00208	CcSEcCtD
Mefloquine—ACHE—Metabolism of proteins—MOGS—bone cancer	0.000299	0.0036	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—RB1—bone cancer	0.000298	0.00359	CbGpPWpGaD
Mefloquine—Hepatobiliary disease—Methotrexate—bone cancer	0.000298	0.00205	CcSEcCtD
Mefloquine—Pneumonia—Epirubicin—bone cancer	0.000296	0.00204	CcSEcCtD
Mefloquine—Agranulocytosis—Methotrexate—bone cancer	0.000294	0.00203	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000292	0.00202	CcSEcCtD
Mefloquine—HBA2—Metabolism—GNA11—bone cancer	0.000291	0.0035	CbGpPWpGaD
Mefloquine—Renal failure—Epirubicin—bone cancer	0.000289	0.002	CcSEcCtD
Mefloquine—Body temperature increased—Cisplatin—bone cancer	0.000289	0.002	CcSEcCtD
Mefloquine—Neuropathy peripheral—Epirubicin—bone cancer	0.000289	0.00199	CcSEcCtD
Mefloquine—ADORA2A—Circadian rythm related genes—GNA11—bone cancer	0.000286	0.00345	CbGpPWpGaD
Mefloquine—ACHE—ATF-2 transcription factor network—MMP2—bone cancer	0.000286	0.00344	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—EZH2—bone cancer	0.000285	0.00343	CbGpPWpGaD
Mefloquine—CYP19A1—Tryptophan metabolism—MDM2—bone cancer	0.000285	0.00343	CbGpPWpGaD
Mefloquine—Sweating—Epirubicin—bone cancer	0.000282	0.00195	CcSEcCtD
Mefloquine—Hepatobiliary disease—Epirubicin—bone cancer	0.000278	0.00192	CcSEcCtD
Mefloquine—Agranulocytosis—Epirubicin—bone cancer	0.000275	0.0019	CcSEcCtD
Mefloquine—Pneumonia—Doxorubicin—bone cancer	0.000274	0.00189	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—GRM4—bone cancer	0.000274	0.0033	CbGpPWpGaD
Mefloquine—Visual impairment—Methotrexate—bone cancer	0.000272	0.00188	CcSEcCtD
Mefloquine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00027	0.00187	CcSEcCtD
Mefloquine—Hypersensitivity—Cisplatin—bone cancer	0.000269	0.00186	CcSEcCtD
Mefloquine—Bradycardia—Epirubicin—bone cancer	0.000269	0.00186	CcSEcCtD
Mefloquine—Renal failure—Doxorubicin—bone cancer	0.000268	0.00185	CcSEcCtD
Mefloquine—Erythema multiforme—Methotrexate—bone cancer	0.000267	0.00184	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000267	0.00184	CcSEcCtD
Mefloquine—BCHE—Metabolism of proteins—MOGS—bone cancer	0.000266	0.00321	CbGpPWpGaD
Mefloquine—Eye disorder—Methotrexate—bone cancer	0.000264	0.00182	CcSEcCtD
Mefloquine—HBA2—Metabolism—CYP3A4—bone cancer	0.000264	0.00318	CbGpPWpGaD
Mefloquine—Tinnitus—Methotrexate—bone cancer	0.000263	0.00182	CcSEcCtD
Mefloquine—Asthenia—Cisplatin—bone cancer	0.000262	0.00181	CcSEcCtD
Mefloquine—Cardiac disorder—Methotrexate—bone cancer	0.000262	0.00181	CcSEcCtD
Mefloquine—Sweating—Doxorubicin—bone cancer	0.000261	0.0018	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ATF1—bone cancer	0.000261	0.00314	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000261	0.00314	CbGpPWpGaD
Mefloquine—Connective tissue disorder—Epirubicin—bone cancer	0.00026	0.00179	CcSEcCtD
Mefloquine—Hepatobiliary disease—Doxorubicin—bone cancer	0.000258	0.00178	CcSEcCtD
Mefloquine—Angiopathy—Methotrexate—bone cancer	0.000256	0.00177	CcSEcCtD
Mefloquine—Visual impairment—Epirubicin—bone cancer	0.000255	0.00176	CcSEcCtD
Mefloquine—Mediastinal disorder—Methotrexate—bone cancer	0.000255	0.00176	CcSEcCtD
Mefloquine—HBA1—Metabolism—ENO2—bone cancer	0.000254	0.00306	CbGpPWpGaD
Mefloquine—Agranulocytosis—Doxorubicin—bone cancer	0.000254	0.00176	CcSEcCtD
Mefloquine—Chills—Methotrexate—bone cancer	0.000253	0.00175	CcSEcCtD
Mefloquine—Diarrhoea—Cisplatin—bone cancer	0.00025	0.00173	CcSEcCtD
Mefloquine—Erythema multiforme—Epirubicin—bone cancer	0.00025	0.00173	CcSEcCtD
Mefloquine—Alopecia—Methotrexate—bone cancer	0.00025	0.00172	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—bone cancer	0.000249	0.00172	CcSEcCtD
Mefloquine—Mental disorder—Methotrexate—bone cancer	0.000247	0.00171	CcSEcCtD
Mefloquine—Eye disorder—Epirubicin—bone cancer	0.000247	0.00171	CcSEcCtD
Mefloquine—Tinnitus—Epirubicin—bone cancer	0.000246	0.0017	CcSEcCtD
Mefloquine—Malnutrition—Methotrexate—bone cancer	0.000246	0.0017	CcSEcCtD
Mefloquine—Erythema—Methotrexate—bone cancer	0.000246	0.0017	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000246	0.00296	CbGpPWpGaD
Mefloquine—Cardiac disorder—Epirubicin—bone cancer	0.000245	0.00169	CcSEcCtD
Mefloquine—Flushing—Epirubicin—bone cancer	0.000245	0.00169	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—bone cancer	0.00024	0.00166	CcSEcCtD
Mefloquine—Angiopathy—Epirubicin—bone cancer	0.00024	0.00166	CcSEcCtD
Mefloquine—Mediastinal disorder—Epirubicin—bone cancer	0.000238	0.00164	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—GRM1—bone cancer	0.000237	0.00286	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000237	0.00286	CbGpPWpGaD
Mefloquine—Chills—Epirubicin—bone cancer	0.000237	0.00164	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000236	0.00285	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—DHFR—bone cancer	0.000236	0.00284	CbGpPWpGaD
Mefloquine—Visual impairment—Doxorubicin—bone cancer	0.000236	0.00163	CcSEcCtD
Mefloquine—Alopecia—Epirubicin—bone cancer	0.000234	0.00161	CcSEcCtD
Mefloquine—Vomiting—Cisplatin—bone cancer	0.000233	0.00161	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—bone cancer	0.000232	0.0016	CcSEcCtD
Mefloquine—Mental disorder—Epirubicin—bone cancer	0.000232	0.0016	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—bone cancer	0.000231	0.0016	CcSEcCtD
Mefloquine—Rash—Cisplatin—bone cancer	0.000231	0.00159	CcSEcCtD
Mefloquine—Dermatitis—Cisplatin—bone cancer	0.00023	0.00159	CcSEcCtD
Mefloquine—Malnutrition—Epirubicin—bone cancer	0.00023	0.00159	CcSEcCtD
Mefloquine—Erythema—Epirubicin—bone cancer	0.00023	0.00159	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—bone cancer	0.000229	0.00158	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—bone cancer	0.000228	0.00158	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—bone cancer	0.000228	0.00157	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—bone cancer	0.000227	0.00157	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—bone cancer	0.000227	0.00157	CcSEcCtD
Mefloquine—HBA2—Metabolism—GSTP1—bone cancer	0.000226	0.00272	CbGpPWpGaD
Mefloquine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000224	0.0027	CbGpPWpGaD
Mefloquine—ABCB1—bone marrow—bone cancer	0.000223	0.00188	CbGeAlD
Mefloquine—ABCB1—spinal cord—bone cancer	0.000222	0.00187	CbGeAlD
Mefloquine—Angiopathy—Doxorubicin—bone cancer	0.000222	0.00153	CcSEcCtD
Mefloquine—Malaise—Methotrexate—bone cancer	0.000222	0.00153	CcSEcCtD
Mefloquine—Muscle spasms—Epirubicin—bone cancer	0.000221	0.00153	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—bone cancer	0.000221	0.00153	CcSEcCtD
Mefloquine—ACHE—ATF-2 transcription factor network—JUN—bone cancer	0.000221	0.00266	CbGpPWpGaD
Mefloquine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000221	0.00266	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—GNA11—bone cancer	0.000221	0.00266	CbGpPWpGaD
Mefloquine—Mediastinal disorder—Doxorubicin—bone cancer	0.00022	0.00152	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—bone cancer	0.00022	0.00152	CcSEcCtD
Mefloquine—Chills—Doxorubicin—bone cancer	0.000219	0.00152	CcSEcCtD
Mefloquine—Nausea—Cisplatin—bone cancer	0.000217	0.0015	CcSEcCtD
Mefloquine—Vision blurred—Epirubicin—bone cancer	0.000217	0.0015	CcSEcCtD
Mefloquine—ADORA1—GPCR ligand binding—SMO—bone cancer	0.000217	0.00261	CbGpPWpGaD
Mefloquine—Alopecia—Doxorubicin—bone cancer	0.000216	0.00149	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000216	0.0026	CbGpPWpGaD
Mefloquine—CYP19A1—Biological oxidations—CYP3A4—bone cancer	0.000216	0.0026	CbGpPWpGaD
Mefloquine—Mental disorder—Doxorubicin—bone cancer	0.000214	0.00148	CcSEcCtD
Mefloquine—Ill-defined disorder—Epirubicin—bone cancer	0.000214	0.00147	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000213	0.00257	CbGpPWpGaD
Mefloquine—Convulsion—Methotrexate—bone cancer	0.000213	0.00147	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—bone cancer	0.000213	0.00147	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—bone cancer	0.000213	0.00147	CcSEcCtD
Mefloquine—CYP19A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000213	0.00256	CbGpPWpGaD
Mefloquine—Agitation—Epirubicin—bone cancer	0.000211	0.00146	CcSEcCtD
Mefloquine—Myalgia—Methotrexate—bone cancer	0.000209	0.00145	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—bone cancer	0.000209	0.00145	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—bone cancer	0.000209	0.00145	CcSEcCtD
Mefloquine—ADORA1—Circadian rythm related genes—CDK4—bone cancer	0.000208	0.00251	CbGpPWpGaD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000208	0.00144	CcSEcCtD
Mefloquine—Malaise—Epirubicin—bone cancer	0.000208	0.00143	CcSEcCtD
Mefloquine—Discomfort—Methotrexate—bone cancer	0.000207	0.00143	CcSEcCtD
Mefloquine—Vertigo—Epirubicin—bone cancer	0.000207	0.00143	CcSEcCtD
Mefloquine—Syncope—Epirubicin—bone cancer	0.000206	0.00142	CcSEcCtD
Mefloquine—Leukopenia—Epirubicin—bone cancer	0.000206	0.00142	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000205	0.00247	CbGpPWpGaD
Mefloquine—Muscle spasms—Doxorubicin—bone cancer	0.000205	0.00141	CcSEcCtD
Mefloquine—Palpitations—Epirubicin—bone cancer	0.000203	0.0014	CcSEcCtD
Mefloquine—Confusional state—Methotrexate—bone cancer	0.000202	0.0014	CcSEcCtD
Mefloquine—Loss of consciousness—Epirubicin—bone cancer	0.000202	0.0014	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—ATF1—bone cancer	0.000201	0.00242	CbGpPWpGaD
Mefloquine—Anaphylactic shock—Methotrexate—bone cancer	0.000201	0.00139	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—bone cancer	0.000201	0.00139	CcSEcCtD
Mefloquine—ADORA1—GPCR downstream signaling—RGS1—bone cancer	0.0002	0.00241	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—GRM4—bone cancer	0.0002	0.00241	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.0002	0.00241	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—CYP3A4—bone cancer	0.0002	0.00241	CbGpPWpGaD
Mefloquine—Convulsion—Epirubicin—bone cancer	0.000199	0.00138	CcSEcCtD
Mefloquine—Hypertension—Epirubicin—bone cancer	0.000199	0.00137	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—bone cancer	0.000198	0.00136	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—bone cancer	0.000197	0.00136	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—bone cancer	0.000196	0.00136	CcSEcCtD
Mefloquine—Myalgia—Epirubicin—bone cancer	0.000196	0.00135	CcSEcCtD
Mefloquine—Chest pain—Epirubicin—bone cancer	0.000196	0.00135	CcSEcCtD
Mefloquine—Arthralgia—Epirubicin—bone cancer	0.000196	0.00135	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—bone cancer	0.000196	0.00135	CcSEcCtD
Mefloquine—Anxiety—Epirubicin—bone cancer	0.000195	0.00135	CcSEcCtD
Mefloquine—Skin disorder—Methotrexate—bone cancer	0.000195	0.00135	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000195	0.00134	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—bone cancer	0.000194	0.00134	CcSEcCtD
Mefloquine—Discomfort—Epirubicin—bone cancer	0.000194	0.00134	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—bone cancer	0.000192	0.00133	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—bone cancer	0.000191	0.00132	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—bone cancer	0.000191	0.00132	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—bone cancer	0.000191	0.00132	CcSEcCtD
Mefloquine—Confusional state—Epirubicin—bone cancer	0.000189	0.00131	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—bone cancer	0.000188	0.0013	CcSEcCtD
Mefloquine—Anaphylactic shock—Epirubicin—bone cancer	0.000188	0.0013	CcSEcCtD
Mefloquine—Oedema—Epirubicin—bone cancer	0.000188	0.0013	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—bone cancer	0.000188	0.00129	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—bone cancer	0.000187	0.00129	CcSEcCtD
Mefloquine—Shock—Epirubicin—bone cancer	0.000185	0.00128	CcSEcCtD
Mefloquine—CYP19A1—Biological oxidations—GSTP1—bone cancer	0.000185	0.00222	CbGpPWpGaD
Mefloquine—Convulsion—Doxorubicin—bone cancer	0.000184	0.00127	CcSEcCtD
Mefloquine—Nervous system disorder—Epirubicin—bone cancer	0.000184	0.00127	CcSEcCtD
Mefloquine—Thrombocytopenia—Epirubicin—bone cancer	0.000184	0.00127	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—bone cancer	0.000184	0.00127	CcSEcCtD
Mefloquine—Tachycardia—Epirubicin—bone cancer	0.000183	0.00127	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000183	0.00126	CcSEcCtD
Mefloquine—Skin disorder—Epirubicin—bone cancer	0.000182	0.00126	CcSEcCtD
Mefloquine—CYP19A1—Metapathway biotransformation—GSTP1—bone cancer	0.000182	0.00219	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—RGS1—bone cancer	0.000182	0.00219	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—GRM4—bone cancer	0.000182	0.00219	CbGpPWpGaD
Mefloquine—Hyperhidrosis—Epirubicin—bone cancer	0.000182	0.00125	CcSEcCtD
Mefloquine—Insomnia—Methotrexate—bone cancer	0.000182	0.00125	CcSEcCtD
Mefloquine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000181	0.00218	CbGpPWpGaD
Mefloquine—Chest pain—Doxorubicin—bone cancer	0.000181	0.00125	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—bone cancer	0.000181	0.00125	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—bone cancer	0.000181	0.00125	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—bone cancer	0.000181	0.00125	CcSEcCtD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000181	0.00218	CbGpPWpGaD
Mefloquine—Paraesthesia—Methotrexate—bone cancer	0.00018	0.00124	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00018	0.00124	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—bone cancer	0.000179	0.00124	CcSEcCtD
Mefloquine—Dyspnoea—Methotrexate—bone cancer	0.000179	0.00124	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—bone cancer	0.000178	0.00123	CcSEcCtD
Mefloquine—Dyspepsia—Methotrexate—bone cancer	0.000177	0.00122	CcSEcCtD
Mefloquine—Hypotension—Epirubicin—bone cancer	0.000175	0.00121	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—bone cancer	0.000175	0.00121	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—bone cancer	0.000174	0.0012	CcSEcCtD
Mefloquine—ADORA1—GPCR downstream signaling—GRM1—bone cancer	0.000174	0.00209	CbGpPWpGaD
Mefloquine—Anaphylactic shock—Doxorubicin—bone cancer	0.000174	0.0012	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—bone cancer	0.000174	0.0012	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—bone cancer	0.000173	0.0012	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—bone cancer	0.000173	0.00119	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000171	0.00118	CcSEcCtD
Mefloquine—HBA1—Metabolism—GSTP1—bone cancer	0.000171	0.00206	CbGpPWpGaD
Mefloquine—Shock—Doxorubicin—bone cancer	0.000171	0.00118	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—bone cancer	0.00017	0.00118	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—bone cancer	0.00017	0.00117	CcSEcCtD
Mefloquine—Insomnia—Epirubicin—bone cancer	0.00017	0.00117	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—bone cancer	0.00017	0.00117	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—bone cancer	0.000169	0.00117	CcSEcCtD
Mefloquine—Paraesthesia—Epirubicin—bone cancer	0.000169	0.00116	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—bone cancer	0.000168	0.00116	CcSEcCtD
Mefloquine—Dyspnoea—Epirubicin—bone cancer	0.000167	0.00116	CcSEcCtD
Mefloquine—ADORA2A—GPCR ligand binding—SMO—bone cancer	0.000167	0.00202	CbGpPWpGaD
Mefloquine—Somnolence—Epirubicin—bone cancer	0.000167	0.00115	CcSEcCtD
Mefloquine—Feeling abnormal—Methotrexate—bone cancer	0.000165	0.00114	CcSEcCtD
Mefloquine—Dyspepsia—Epirubicin—bone cancer	0.000165	0.00114	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—bone cancer	0.000164	0.00113	CcSEcCtD
Mefloquine—ACHE—Metabolism of proteins—TUBB4B—bone cancer	0.000164	0.00197	CbGpPWpGaD
Mefloquine—Decreased appetite—Epirubicin—bone cancer	0.000163	0.00113	CcSEcCtD
Mefloquine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.000163	0.00196	CbGpPWpGaD
Mefloquine—Hypotension—Doxorubicin—bone cancer	0.000162	0.00112	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Epirubicin—bone cancer	0.000162	0.00112	CcSEcCtD
Mefloquine—Fatigue—Epirubicin—bone cancer	0.000162	0.00112	CcSEcCtD
Mefloquine—ADORA2A—Circadian rythm related genes—CDK4—bone cancer	0.000161	0.00194	CbGpPWpGaD
Mefloquine—Urticaria—Methotrexate—bone cancer	0.000159	0.0011	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—bone cancer	0.000159	0.0011	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—bone cancer	0.000159	0.0011	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000158	0.00109	CcSEcCtD
Mefloquine—ADORA1—Signaling by GPCR—GRM1—bone cancer	0.000158	0.0019	CbGpPWpGaD
Mefloquine—Insomnia—Doxorubicin—bone cancer	0.000157	0.00109	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—bone cancer	0.000156	0.00108	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—bone cancer	0.000155	0.00107	CcSEcCtD
Mefloquine—ADORA2A—GPCR downstream signaling—RGS1—bone cancer	0.000155	0.00186	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—GRM4—bone cancer	0.000155	0.00186	CbGpPWpGaD
Mefloquine—Feeling abnormal—Epirubicin—bone cancer	0.000155	0.00107	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—bone cancer	0.000154	0.00107	CcSEcCtD
Mefloquine—Gastrointestinal pain—Epirubicin—bone cancer	0.000154	0.00106	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—bone cancer	0.000153	0.00106	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—bone cancer	0.000151	0.00104	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00015	0.00104	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—bone cancer	0.00015	0.00103	CcSEcCtD
Mefloquine—Urticaria—Epirubicin—bone cancer	0.000149	0.00103	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—bone cancer	0.000149	0.00179	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000149	0.00179	CbGpPWpGaD
Mefloquine—Body temperature increased—Epirubicin—bone cancer	0.000148	0.00103	CcSEcCtD
Mefloquine—Abdominal pain—Epirubicin—bone cancer	0.000148	0.00103	CcSEcCtD
Mefloquine—Hypersensitivity—Methotrexate—bone cancer	0.000148	0.00102	CcSEcCtD
Mefloquine—BCHE—Metabolism of proteins—TUBB4B—bone cancer	0.000146	0.00176	CbGpPWpGaD
Mefloquine—Asthenia—Methotrexate—bone cancer	0.000144	0.000994	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—bone cancer	0.000143	0.000989	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—bone cancer	0.000142	0.000981	CcSEcCtD
Mefloquine—Pruritus—Methotrexate—bone cancer	0.000142	0.00098	CcSEcCtD
Mefloquine—ACHE—Metabolism of proteins—TUBB2A—bone cancer	0.000141	0.0017	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—NDUFA12—bone cancer	0.000141	0.0017	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—GRM4—bone cancer	0.000141	0.00169	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—RGS1—bone cancer	0.000141	0.00169	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—BRAF—bone cancer	0.00014	0.00168	CbGpPWpGaD
Mefloquine—Hypersensitivity—Epirubicin—bone cancer	0.000138	0.000955	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—bone cancer	0.000138	0.000953	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—bone cancer	0.000137	0.000948	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—bone cancer	0.000137	0.000948	CcSEcCtD
Mefloquine—Diarrhoea—Methotrexate—bone cancer	0.000137	0.000948	CcSEcCtD
Mefloquine—Asthenia—Epirubicin—bone cancer	0.000135	0.00093	CcSEcCtD
Mefloquine—ADORA1—Circadian rythm related genes—JUN—bone cancer	0.000134	0.00162	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—GRM1—bone cancer	0.000134	0.00162	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000134	0.00161	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000133	0.00161	CbGpPWpGaD
Mefloquine—Pruritus—Epirubicin—bone cancer	0.000133	0.000917	CcSEcCtD
Mefloquine—Dizziness—Methotrexate—bone cancer	0.000133	0.000916	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000131	0.00158	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NDUFA12—bone cancer	0.000129	0.00156	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000129	0.00156	CbGpPWpGaD
Mefloquine—Diarrhoea—Epirubicin—bone cancer	0.000128	0.000887	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—bone cancer	0.000128	0.000884	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—bone cancer	0.000128	0.000881	CcSEcCtD
Mefloquine—Rash—Methotrexate—bone cancer	0.000127	0.000874	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—bone cancer	0.000126	0.000873	CcSEcCtD
Mefloquine—BCHE—Metabolism of proteins—TUBB2A—bone cancer	0.000126	0.00152	CbGpPWpGaD
Mefloquine—Headache—Methotrexate—bone cancer	0.000126	0.000868	CcSEcCtD
Mefloquine—BCHE—Metabolism—NDUFA12—bone cancer	0.000126	0.00151	CbGpPWpGaD
Mefloquine—Asthenia—Doxorubicin—bone cancer	0.000125	0.000861	CcSEcCtD
Mefloquine—Dizziness—Epirubicin—bone cancer	0.000124	0.000857	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—bone cancer	0.000123	0.000849	CcSEcCtD
Mefloquine—ADORA2A—Signaling by GPCR—GRM1—bone cancer	0.000122	0.00147	CbGpPWpGaD
Mefloquine—Vomiting—Epirubicin—bone cancer	0.000119	0.000824	CcSEcCtD
Mefloquine—Nausea—Methotrexate—bone cancer	0.000119	0.000823	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—bone cancer	0.000119	0.000821	CcSEcCtD
Mefloquine—Rash—Epirubicin—bone cancer	0.000118	0.000818	CcSEcCtD
Mefloquine—Dermatitis—Epirubicin—bone cancer	0.000118	0.000817	CcSEcCtD
Mefloquine—Headache—Epirubicin—bone cancer	0.000118	0.000812	CcSEcCtD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—bone cancer	0.000117	0.00141	CbGpPWpGaD
Mefloquine—HBA2—Metabolism—PTGS2—bone cancer	0.000117	0.00141	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—NT5C3A—bone cancer	0.000117	0.00141	CbGpPWpGaD
Mefloquine—Dizziness—Doxorubicin—bone cancer	0.000115	0.000793	CcSEcCtD
Mefloquine—ADORA2A—Signaling by NGF—KIT—bone cancer	0.000114	0.00138	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—BRAF—bone cancer	0.000114	0.00138	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000113	0.00137	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—GNA11—bone cancer	0.000112	0.00135	CbGpPWpGaD
Mefloquine—Nausea—Epirubicin—bone cancer	0.000112	0.00077	CcSEcCtD
Mefloquine—ADORA1—Signaling by GPCR—SMO—bone cancer	0.000111	0.00134	CbGpPWpGaD
Mefloquine—Vomiting—Doxorubicin—bone cancer	0.00011	0.000763	CcSEcCtD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.00011	0.00133	CbGpPWpGaD
Mefloquine—Rash—Doxorubicin—bone cancer	0.00011	0.000756	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—bone cancer	0.000109	0.000756	CcSEcCtD
Mefloquine—Headache—Doxorubicin—bone cancer	0.000109	0.000752	CcSEcCtD
Mefloquine—ADORA1—Signaling Pathways—GRM4—bone cancer	0.000108	0.0013	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—RGS1—bone cancer	0.000108	0.0013	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—BRAF—bone cancer	0.000107	0.00129	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NT5C3A—bone cancer	0.000107	0.00129	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—NT5C3A—bone cancer	0.000104	0.00125	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—JUN—bone cancer	0.000104	0.00125	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000103	0.00124	CbGpPWpGaD
Mefloquine—Nausea—Doxorubicin—bone cancer	0.000103	0.000713	CcSEcCtD
Mefloquine—BCHE—Transmission across Chemical Synapses—BRAF—bone cancer	0.000102	0.00123	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—GNA11—bone cancer	0.000102	0.00123	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—IL3—bone cancer	0.000102	0.00122	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	9.93e-05	0.0012	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—EIF2S1—bone cancer	9.85e-05	0.00119	CbGpPWpGaD
Mefloquine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	9.64e-05	0.00116	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	9.57e-05	0.00115	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—JUN—bone cancer	9.57e-05	0.00115	CbGpPWpGaD
Mefloquine—ACHE—Transmission across Chemical Synapses—MDM2—bone cancer	9.57e-05	0.00115	CbGpPWpGaD
Mefloquine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	9.5e-05	0.00114	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.4e-05	0.00113	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—GRM1—bone cancer	9.32e-05	0.00112	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.28e-05	0.00112	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL3—bone cancer	9.22e-05	0.00111	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—MDM2—bone cancer	9e-05	0.00108	CbGpPWpGaD
Mefloquine—ADORA1—Circadian rythm related genes—TP53—bone cancer	8.87e-05	0.00107	CbGpPWpGaD
Mefloquine—HBA1—Metabolism—PTGS2—bone cancer	8.86e-05	0.00107	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—EIF2S1—bone cancer	8.79e-05	0.00106	CbGpPWpGaD
Mefloquine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	8.79e-05	0.00106	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—BRAF—bone cancer	8.75e-05	0.00105	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—GNA11—bone cancer	8.65e-05	0.00104	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	8.63e-05	0.00104	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—SMO—bone cancer	8.59e-05	0.00103	CbGpPWpGaD
Mefloquine—BCHE—Transmission across Chemical Synapses—MDM2—bone cancer	8.54e-05	0.00103	CbGpPWpGaD
Mefloquine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.32e-05	0.001	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—GRM4—bone cancer	8.3e-05	0.001	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—RGS1—bone cancer	8.3e-05	0.001	CbGpPWpGaD
Mefloquine—CYP2D6—Biological oxidations—GSTP1—bone cancer	8.24e-05	0.000993	CbGpPWpGaD
Mefloquine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	8.13e-05	0.000979	CbGpPWpGaD
Mefloquine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—bone cancer	8e-05	0.000963	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	7.86e-05	0.000947	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—GNA11—bone cancer	7.85e-05	0.000946	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—IL3—bone cancer	7.84e-05	0.000944	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	7.84e-05	0.000944	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—BRAF—bone cancer	7.81e-05	0.00094	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—EGFR—bone cancer	7.53e-05	0.000906	CbGpPWpGaD
Mefloquine—ACHE—Neuronal System—MDM2—bone cancer	7.33e-05	0.000883	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—GRM1—bone cancer	7.2e-05	0.000867	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL3—bone cancer	7.12e-05	0.000858	CbGpPWpGaD
Mefloquine—ADORA2A—Circadian rythm related genes—TP53—bone cancer	6.85e-05	0.000825	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	6.79e-05	0.000817	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	6.77e-05	0.000815	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SMO—bone cancer	6.57e-05	0.000791	CbGpPWpGaD
Mefloquine—BCHE—Neuronal System—MDM2—bone cancer	6.54e-05	0.000788	CbGpPWpGaD
Mefloquine—CYP19A1—Integrated Breast Cancer Pathway—TP53—bone cancer	6.32e-05	0.000761	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by NGF—EGFR—bone cancer	6.15e-05	0.000741	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NDUFA12—bone cancer	6.13e-05	0.000738	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—GNA11—bone cancer	6.01e-05	0.000724	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	5.83e-05	0.000702	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NDUFA12—bone cancer	5.78e-05	0.000696	CbGpPWpGaD
Mefloquine—ACHE—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	5.7e-05	0.000686	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—ATF1—bone cancer	5.59e-05	0.000673	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL3—bone cancer	5.45e-05	0.000656	CbGpPWpGaD
Mefloquine—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.39e-05	0.000649	CbGpPWpGaD
Mefloquine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.31e-05	0.00064	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ENO2—bone cancer	5.11e-05	0.000616	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NT5C3A—bone cancer	5.08e-05	0.000612	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SMO—bone cancer	5.07e-05	0.000611	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NT5C3A—bone cancer	4.79e-05	0.000576	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—DHFR—bone cancer	4.74e-05	0.000571	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ENO2—bone cancer	4.7e-05	0.000566	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TGFBR2—bone cancer	4.66e-05	0.000561	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—GNA11—bone cancer	4.64e-05	0.000559	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ENO2—bone cancer	4.56e-05	0.000549	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GNA11—bone cancer	4.43e-05	0.000534	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IGF1R—bone cancer	4.38e-05	0.000528	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—DHFR—bone cancer	4.36e-05	0.000525	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.32e-05	0.000521	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ATF1—bone cancer	4.31e-05	0.000519	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—DHFR—bone cancer	4.23e-05	0.000509	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL3—bone cancer	4.21e-05	0.000507	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.17e-05	0.000502	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GNA11—bone cancer	4.07e-05	0.00049	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of proteins—MMP2—bone cancer	4.03e-05	0.000486	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CYP3A4—bone cancer	4.02e-05	0.000484	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4e-05	0.000481	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GNA11—bone cancer	3.95e-05	0.000476	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NDUFA12—bone cancer	3.78e-05	0.000455	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.76e-05	0.000452	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CYP3A4—bone cancer	3.69e-05	0.000445	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.67e-05	0.000442	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TGFBR2—bone cancer	3.6e-05	0.000433	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of proteins—MMP2—bone cancer	3.6e-05	0.000433	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CYP3A4—bone cancer	3.58e-05	0.000432	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.57e-05	0.000429	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—GSTP1—bone cancer	3.44e-05	0.000414	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IGF1R—bone cancer	3.38e-05	0.000408	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KIT—bone cancer	3.18e-05	0.000383	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—GSTP1—bone cancer	3.16e-05	0.00038	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NT5C3A—bone cancer	3.13e-05	0.000377	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—GSTP1—bone cancer	3.07e-05	0.000369	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—BRAF—bone cancer	2.99e-05	0.00036	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.95e-05	0.000356	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—EGFR—bone cancer	2.9e-05	0.000349	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MDM2—bone cancer	2.5e-05	0.000302	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.48e-05	0.000299	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KIT—bone cancer	2.45e-05	0.000296	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—BRAF—bone cancer	2.31e-05	0.000278	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—EGFR—bone cancer	2.24e-05	0.000269	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ENO2—bone cancer	2.22e-05	0.000268	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—JUN—bone cancer	2.18e-05	0.000262	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MMP9—bone cancer	2.12e-05	0.000255	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ENO2—bone cancer	2.1e-05	0.000252	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—DHFR—bone cancer	2.06e-05	0.000249	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—DHFR—bone cancer	1.94e-05	0.000234	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MDM2—bone cancer	1.93e-05	0.000233	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GNA11—bone cancer	1.93e-05	0.000232	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GNA11—bone cancer	1.82e-05	0.000219	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS2—bone cancer	1.78e-05	0.000214	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP3A4—bone cancer	1.75e-05	0.000211	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EGFR—bone cancer	1.71e-05	0.000206	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JUN—bone cancer	1.68e-05	0.000202	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.65e-05	0.000198	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS2—bone cancer	1.64e-05	0.000197	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MMP9—bone cancer	1.63e-05	0.000197	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS2—bone cancer	1.59e-05	0.000191	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTP1—bone cancer	1.5e-05	0.00018	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—bone cancer	1.44e-05	0.000173	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTP1—bone cancer	1.41e-05	0.00017	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ENO2—bone cancer	1.37e-05	0.000165	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EGFR—bone cancer	1.32e-05	0.000159	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—DHFR—bone cancer	1.27e-05	0.000153	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GNA11—bone cancer	1.19e-05	0.000143	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—bone cancer	1.11e-05	0.000134	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTP1—bone cancer	9.21e-06	0.000111	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS2—bone cancer	7.75e-06	9.33e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS2—bone cancer	7.3e-06	8.79e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS2—bone cancer	4.77e-06	5.75e-05	CbGpPWpGaD
